INTRODUCTION {#sec1}
============

Obesity has long been associated with worse prognosis of viral infections ([@B30]). Higher mortality rates and a prolonged, more severe clinical course was observed in obese people in the 1957--1960 "Asian" and the 1968 "Hong Kong" influenzas ([@B22], [@B39]), whereas more recently obesity was recognized as a predisposing factor for worse clinical outcomes and death in the 2009 H1N1 pandemic. In accordance with these previous results, recent reports have demonstrated a strong association of worse clinical outcomes in COVID-19 disease with obesity, even in the absence of any other comorbidity. In a study in a single French center, obesity \[body mass index (BMI) \> 30 kg/m^2^\] and severe obesity (BMI \> 35 kg/m^2^) were present in 47.6% and 28.2% of severe cases, respectively, whereas the need for interventional mechanical ventilation (IMV) increased with BMI categories independently of age, diabetes, and hypertension ([@B31]). Petrilli et al. ([@B25]) showed that among other factors, BMI \> 40 kg/m^2^ was a strong hospitalization risk factor, with an odds ratio (OR) of 6.2 in an academic health system in New York City. In a retrospective study by Lighter et al. ([@B17]), patients aged under 60 yr with a BMI of 30--34 kg/m^2^ were two and 1.8 times more likely to be admitted to acute and critical care, respectively, compared with individuals with BMI \<30 kg/m^2^, with the risk escalating for BMI \>35 kg/m^2^ (2.2 and 3.6 times, respectively). The unfavorable effects of obesity in the course of viral infections have been attributed to the metabolic derangement and chronic inflammation of the adipose tissue depots leading to blunted macrophage activation and impaired T and B lymphocyte responses. However, whether these mechanisms apply to the novel coronavirus infection remains unclear. In this review, we briefly present the pathophysiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We then discuss the possible mechanisms through which the metabolic and immune derangement in obesity can lead to more severe clinical outcomes, with their understanding being necessary in the search for novel treatment targets in the future.

PROCESS OF VIRAL INFECTION {#sec2}
==========================

SARS-CoV-2 consists of four different types of structural proteins: spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins. The entry into host cells is mediated by the S protein, which comprises two separate subunits: S1 subunit, responsible for binding to the host cell receptor, and S2 subunit, responsible for the fusion between viral and cellular membranes. The cellular receptor for the virus is the angiotensin-converting enzyme 2 (ACE2), which is expressed in type I and type II alveolar epithelial cells in the lungs as well as in many other tissues such as the heart, the endothelium, the kidneys, and the pancreas ([@B23]). After binding, serine proteases such as TMPRSS2 mediate the cleavage of the spike, and then proteases such as furin release the spike fusion peptide and facilitate viral entry into the cells through endosomes. The infection results in increased cell apoptosis, which triggers the activation of proinflammatory cytokines and chemokines and the recruitment of inflammatory cells. On the other hand, the virus itself causes increased apoptosis of lymphocytes (CD3, CD4, and CD8 T cells), and the subsequent lymphocytopenia and impaired function of lymphocytes ends up in a fulminant hypercytokinemia known as "cytokine storm" ([@B40]). This condition resembles secondary hemophagocytic lymphohistiocytosis (sHLH) or macrophage activation syndrome (MAS), a common finding in severe viral infections and sepsis, which is characterized by excessive circulating levels of IL-6, IL-2, IL-7, TNFα, CXC-chemokine ligand 10 (CXCL10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP1α), and other proinflammatory molecules, and is associated with progression to acute respiratory distress syndrome (ARDS) and multiorgan failure ([@B21]).

OBESITY AS A RISK FACTOR FOR COVID-19: POSSIBLE MECHANISMS {#sec3}
==========================================================

As we mentioned above, the association of obesity with prolonged recovery and worse clinical outcomes in viral infections has long been known. In recent years, as the role of adipose tissue as a distinct endocrine organ is being elucidated, obesity has been considered an independent risk factor for increased susceptibility to infections, sepsis, and higher mortality ([@B9]). This increased risk has been attributed to the state of chronic, low-grade inflammation that characterizes obesity, which results in metabolic and immune derangement. As the pathophysiology of SARS-CoV-2 infection is being unraveled, the links between the severity of clinical presentation and the dysmetabolic background are revealed ([Fig. 1](#F0001){ref-type="fig"}).

![Possible mechanisms through which obesity leads to worse COVID-19 outcomes. ARDS, acute respiratory distress syndrome; LV, left ventricle; MAS, macrophage activation syndrome; NO, nitric oxide; RAAS, renin-angiotensin-aldosterone system; VTE, venous thromboembolism.](zh10072083930001){#F0001}

Chronic Inflammation and Immune Dysregulation {#sec3-1}
---------------------------------------------

The dysfunctional hypertrophic adipocytes in obesity produce an excessive amount of cytokines such as IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1/CCL2), leptin, and plasminogen activator inhibitor-1 (PAI-1), among others, which leads to the increased recruitment of macrophages, especially polarized M1 macrophages ([@B12], [@B19]). These cells, in turn, produce high amounts of proinflammatory molecules like IL-1β, IL-6, IL-8, TNFα, and MCP-1 ([@B18]), an effect that is enhanced also by the action of the increased circulating levels of free fatty acids (FFAs) through the NF-κB pathway ([@B35]). The cumulative effect of these actions is a state of chronic inflammation and hypercytokinemia, which leads to defective innate immunity and creates a conducive ground for the hyperinflammatory response mediated through MAS in severe COVID-19 cases ([@B10]). The adaptive immunity is also adversely affected in obesity, with several studies showing a decline in naïve CD4+ T cells, as well as an imbalance of CD4+ T helper cells toward Th17 and Th22 proinflammatory subsets ([@B9], [@B20]). Similarly, in patients with COVID-19, peripheral counts of CD4+ and CD8+ T cells are low, but with a higher ratio of proinflammatory Th17 cells ([@B10]). Even more interestingly, the presence of increased levels of IL-1β in patients with COVID-19 infection suggests that cell pyroptosis, mediated through the activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, might be strongly involved in the pathogenesis of the infection ([@B13]). The role of inflammasome activation has already been pointed out in studies on other coronavirus infections, where it was demonstrated that Viroporin 3a activated the NLRP3 inflammasome during the SARS-CoV infection ([@B8]), whereas another study on MERS-CoV infection revealed increased amounts of pyroptotic markers (caspase-1 and IL-1β) in the patient group ([@B15]). Even more importantly, in a study by Grailer et al. ([@B11]) in mice, the presence of acute lung injury (ALI) after airway instillation of lipopolysaccharide (LPS) was dependent on availability of NLRP3 and caspase-1, which are known features of the NLRP3 inflammasome. As numerous studies both in humans and animal models have shown, NLRP3 expression is increased in obesity, rendering it a pivotal factor in recruitment of macrophages and immune activation ([@B16], [@B27]). Therefore, agents that inhibit its action, such as colchicine, seem promising in the treatment of specific COVID-19 patients. In addition, agents such as anakinra, an IL-1 blocker, and tocilizumab, an IL-6 blocker, which have proven beneficial in the treatment of rheumatoid arthritis, which is accompanied as well by an excessive cytokine release, have been tested in randomized controlled trials (RCTs) in severe cases of COVID-19, with favorable results and unremarkable adverse events so far ([@B29], [@B37]).

Endothelial Dysfunction and Arterial Stiffness {#sec3-2}
----------------------------------------------

A recent report by Varga et al. ([@B34]) pointed out for the first time the role of the endothelium in the pathogenesis of COVID-19. More specifically, postmortem histology of three patients with severe infection revealed viral inclusion structures in endothelial cells, accumulation of inflammatory cells associated with the endothelium, congestion of the small lung vessels, and endothelitis of the submucosal vessels of the small intestine, implying that the virus uses the ACE2 receptors expressed on endothelial cells in a pattern similar to that of alveolar infection, and therefore, the clinical presentation might be worse in vulnerable patients with preexisting endothelial dysfunction. Obesity is such a typical example, and the mechanisms that lead to vascular abnormalities are various. The hyperinsulinemia and insulin resistance that is a common feature of obesity leads to reduction in the insulin-stimulated phosphoinositide 3-kinase (PI3K) endothelial nitric oxidase synthase (eNOS) signaling pathway, reducing the vasculoprotective effects of nitric oxide (NO) and its anti-inflammatory actions ([@B4]). Increased oxidative stress due to RAAS-induced activation of NADPH oxidase, xanthine oxidase, and mitochondrial oxidative stress results in increased destruction of NO, and its decreased bioavailability further induces macrophage activation ([@B3]). The chronic exposure of endothelial cells to the increased circulating levels of leptin observed in obesity leads to a decreased NO production and increased MCP-1 expression, which further enhances leukocyte infiltration into vascular cells ([@B5], [@B32]). Perivascular adipose tissue (PVAT), exerting anticontractile effects on the endothelium in lean individuals, contributes to vasoconstriction and endothelial malfunction in obesity via increased secretion of TNFα, IL-6, reactive oxygen species (ROS), and chemerin while downregulating NO production ([@B26]). Consistent with the favorable results in hypercytokinemia and acute hyperinflammatory state, the administration of tocilizumab to rheumatoid arthritis patients has been shown to improve pulse wave velocity and brachial blood pressure, which were used as indices of vascular function, and a similar benefit in COVID-19 patients could thus be presumed ([@B14]).

Cardiovascular Events and Thrombosis {#sec3-3}
------------------------------------

Another serious consideration in SARS-CoV-2 infection is its cardiovascular manifestations. Acute cardiac injury is highly prevalent in patients with COVID-19 and is associated with worse clinical outcomes ([@B13], [@B41]). Although the relatively high rate of heart failure (23%) that was observed in patients with COVID-19 could not be explicitly attributed to exacerbation of a preexisting condition or a new cardiomyopathy ([@B7], [@B41]), the presence of acute myocarditis was the definite cause of death in 7% of patients in a case series of 150 patients with COVID-19, whereas in other studies, postmortem histology revealed fulminant myocarditis with the presence of inflammatory mononuclear infiltrates in myocardial tissue ([@B28], [@B38]). The risk of venous thromboembolism also seems important, as in a significant percentage of patients with severe infection, elevated levels of D-dimers have been observed, whereas ∼71% of patients met clinical criteria for disseminated intravascular coagulation (DIC) ([@B33], [@B41]). Obesity is a well-established risk factor for cardiovascular disease (CVD) both per se and through its common comorbidities, such as insulin resistance (IR), diabetes mellitus (DM), and hypertension. The most common alteration in cardiac morphology in obesity is left ventricular (LV) hypertrophy, with hypertension and IR being important determinants of the LV mass ([@B1], [@B2]). In addition, obesity is associated with activation of the renin-angiotensin-aldosterone system (RAAS), which leads to increased levels of angiotensin II, with direct effects on the myocardium ([@B36]). Apart from structural changes, obesity is associated with LV diastolic dysfunction and heart failure ([@B1], [@B2], [@B24]). Chronic inflammation by the proinflammatory cytokines mentioned above leads to upregulation of procoagulant factors (like the tissue factor) and adhesion molecules (like P-selectin), downregulation of anticoagulant regulatory proteins (such as tissue factor pathway inhibitor, antithrombin, and the protein C anticoagulation system), increased thrombin generation, and enhanced platelet activation, thus increasing the risk for thrombosis ([@B6]). Again, in patients with rheumatoid arthritis, the administration of anakinra (mainly) and tocilizumab resulted in a simultaneous improvement in oxidative stress and myocardial deformation, rendering these agents a potential treatment option for patients with COVID-19 and cardiovascular manifestations ([@B14]).

CONCLUSIONS {#sec4}
===========

Obesity has emerged as a major risk factor for worse COVID-19 outcomes. Chronic inflammation and oxidative stress, hypercytokinemia, immune dysregulation, endothelial dysfunction, and cardiovascular abnormalities are all possible mechanisms through which the excess in adipose tissue could lead to the acute hyperinflammatory state that characterizes severe SARS-CoV-2 infections and is responsible for its complications. The lessons learned from other diseases with a similar inflammatory profile, such as rheumatoid arthritis, provide useful insights into the better understanding of these mechanisms and, above all, propose that patients with obesity could be appropriate candidates for the use of agents such as colchicine and anti-IL-1 and anti-IL-6 compounds early in the course of the disease, benefiting from the amelioration of their preexisting, proinflammatory state. Of course, large RCTs are necessary to further clarify the pathways through which metabolic derangement leads to worse COVID-19 outcomes and establish the ideal treatment regimen for each individual patient.
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